Murat O. Arcasoy
Experienced in Blood Clots

Dr. Murat O. Arcasoy

Hematology Oncology | Hematology | Oncology
Duke University Medical Center, Box 3912 Dumc, 
Durham, NC 
Accepting New Patients
Experienced in Blood Clots
Duke University Medical Center, Box 3912 Dumc, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Murat Arcasoy is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Arcasoy is rated as an Experienced provider by MediFind in the treatment of Blood Clots. His top areas of expertise are Essential Thrombocythemia, Polycythemia Vera, Myelofibrosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Aspiration. Dr. Arcasoy is currently accepting new patients.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 3 clinical trials in the study of Blood Clots.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Piedmont
  • HMO
  • POS

Locations

Duke University Medical Center, Box 3912 Dumc, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
Enrollment Status: Terminated
Publish Date: November 15, 2022
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Enrollment Status: Completed
Publish Date: December 13, 2018
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Enrollment Status: Completed
Publish Date: January 11, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

34 Total Publications

Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.
Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.
Journal: Clinical advances in hematology & oncology : H&O
Published: March 06, 2024
Similar Doctors
Elite in Blood Clots
Dr. Nigel S. Key
Hematology Oncology | Hematology
Elite in Blood Clots
Dr. Nigel S. Key
Hematology Oncology | Hematology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.5 miles away)
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Nigel Key is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Key is rated as an Elite provider by MediFind in the treatment of Blood Clots. His top areas of expertise are Hemophilia B, Hemophilia A, Blood Clots, Sickle Cell Disease, and Hip Replacement. Dr. Key is currently accepting new patients.

Distinguished in Blood Clots
Dr. Ara Metjian
Hematology
Distinguished in Blood Clots
Dr. Ara Metjian
Hematology

Duke Health Integrated Practice Inc

234 Crooked Creek Pkwy, 
Durham, NC 
 (6.4 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ara Metjian is a Hematologist in Durham, North Carolina. Dr. Metjian is rated as a Distinguished provider by MediFind in the treatment of Blood Clots. His top areas of expertise are Purpura, Thrombocytopenia, Blood Clots, and Thrombotic Thrombocytopenic Purpura.

Advanced in Blood Clots
Dr. Raj S. Kasthuri
Hematology | Oncology
Advanced in Blood Clots
Dr. Raj S. Kasthuri
Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.5 miles away)
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Raj Kasthuri is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Kasthuri is rated as a Distinguished provider by MediFind in the treatment of Blood Clots. His top areas of expertise are Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformation, Thrombocytopenia, Venous Thromboembolism (VTE), and Splenectomy. Dr. Kasthuri is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Arcasoy's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 9 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile